Högskolan i Skövde

his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Utilizing CRISPR/cas9-mediated technology to treat inherited retinal diseases: A systematic review
University of Skövde, School of Bioscience.
2022 (English)Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Inherited retinal diseases are considered as a leading cause of vision loss in a young population. Neither a permanent cure nor long-term treatment has yet been discovered. However, treating congenital visual impairment by utilizing a sequence-specific nuclease gene editing tool, CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9), has appeared to have a positive impact in restoring eyesight. The following systematic review was implemented to gain more knowledge about the safety and efficiency features of CRISPR/Cas9 technology when used in clinical trials to treat inherited retinal diseases (IRDs). The review focuses on trials with Leber Congenital Amaurosis and Autosomal Dominant Retinitis Pigmentosa, common childhood IRDs. The studies were synthesized in a proportional meta-analysis using MedCalc software, and supplemented with a narrative literature review, considering both qualitative and quantitative data. The review covers different aspects related tothe use of CRISPR/Cas9s and provides an overview of IRDs and future treatment methods. In conclusion, CRISPR/Cas9, indeed, is seen as a potential technique to treat IRDs. However, different complications do arise, and researchers need to be reminded of the side effects and downsides of CRISPR/Cas9. So, they can further enhance this innovative gene-editing technique in exchange for ultimately achieving long-term treatments for blindness and other inherited diseases. 

Place, publisher, year, edition, pages
2022. , p. 36
National Category
Biochemistry and Molecular Biology
Identifiers
URN: urn:nbn:se:his:diva-22047OAI: oai:DiVA.org:his-22047DiVA, id: diva2:1710188
Subject / course
Bioscience
Educational program
Bioscience - Molecular Biodesign
Supervisors
Examiners
Note

Det finns övrigt digitalt material (t.ex. film-, bild- eller ljudfiler) eller modeller/artefakter tillhörande examensarbetet som ska skickas till arkivet.

Available from: 2022-11-11 Created: 2022-11-11 Last updated: 2022-11-11Bibliographically approved

Open Access in DiVA

fulltext(1310 kB)303 downloads
File information
File name FULLTEXT01.pdfFile size 1310 kBChecksum SHA-512
ea7cf01a0ec43fc9a3b039773a740beea14280169f4bad8c69926472205f907992be73d97bfe1f0b509367e7cb06e50c407e468ec807585d3e4703686a681676
Type fulltextMimetype application/pdf

By organisation
School of Bioscience
Biochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 303 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 572 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf